Russell Herndon

Russell Herndon is a seasoned executive in the biopharmaceutical and biotechnology sectors, currently serving as Chief Business Officer at Olaris, Inc. since March 2022, where the company focuses on advancing precision diagnostics through metabolomics and machine learning. Prior to this role, Russell was the Chief Executive Officer of MediSix Therapeutics from September 2019 to December 2020, leading efforts in developing innovative cellular therapies for T cell malignancies. Russell’s extensive experience includes serving as President and CEO of Hydra Biosciences (2006-2019), and holding leadership positions such as President and COO at Antigenics Inc. and President at Genzyme Tissue Repair. Russell's career began as VP of Regulatory Affairs at Genzyme Corporation, following foundational roles in product standards and quality assurance at Paco Research. Russell holds a Bachelor of Science in Biology from Barton College and a PMD from Harvard Business School.